Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.00.

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, Weiss Ratings raised shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.59 on Thursday. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The firm has a market cap of $423.19 million, a price-to-earnings ratio of -1.50 and a beta of 2.15. The company has a 50 day moving average price of $2.04 and a 200-day moving average price of $1.74. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. The company had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Equities research analysts forecast that Autolus Therapeutics will post -0.76 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in AUTL. QRG Capital Management Inc. raised its holdings in Autolus Therapeutics by 67.7% in the 2nd quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock valued at $29,000 after acquiring an additional 7,400 shares during the last quarter. GAMMA Investing LLC lifted its stake in Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after purchasing an additional 8,309 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after purchasing an additional 11,197 shares during the last quarter. R Squared Ltd boosted its holdings in shares of Autolus Therapeutics by 48.4% during the 1st quarter. R Squared Ltd now owns 39,575 shares of the company’s stock worth $55,000 after purchasing an additional 12,915 shares during the last quarter. Finally, Waverly Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $37,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for the treatment of cancer. The company’s platform is designed to genetically engineer T cells so they can recognize cancer targets, remain active in the body, and potentially reduce some limitations associated with conventional cell therapies.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States as Aucatzyl.